Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.
By S. Nissen, S. Nicholls, I. Sipahi, Peter Libby, J. Raichlen, Christie M. Ballantyne, J. Davignon, Raimund Erbel, J C Fruchart, J. Tardif and 6 more. Journal of the American Medical Association (JAMA), 2006
2,091 citations recorded by the source corpus.
Subfields: Radiology, Nuclear Medicine and Imaging, Surgery
View Paper: https://www.semanticscholar.org/paper/a8c461306514f2fe6ffd2b5768b88ed79096bb83
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Radiology, Nuclear Medicine and Imaging
In Surgery
Citations in the corpus
- Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. (2007, methodology): “ACAT Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE; performed at 52 sites in the United States from December 2002 to July 2005),(24) and A Study to Evaluate the Effect of Rosuvastatin on Intravascular-Ultrasound Derived Indices of Coronary Atheroma Burden (ASTEROID; performed at 53 si”
- European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) (2012, positive): “or even contribute to regression of coronary atherosclerosis.(495) Therefore, they should be used as the drugs of first”
- 2016 European Guidelines on cardiovascular disease prevention in clinical practice (2016, background): “Statins at doses that effectively reduce LDL-C by at least 50% also seem to halt progression or even contribute to regression of coronary atherosclerosis.(373) Statins also lower triglycerides, and meta-analysis evidence shows statins may also lower pancreatitis risk.”
- Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. (2007, result): “0% compared with baseline concentrations; these lipid effects of rosuvastatin are consistent with previous studies.(6,11,12,28) The 40-mg dose of rosuvastatin used in this study is not a recommended starting dose but was chosen to provide the maximum efficacy expected to slow or delay progression of”
- 2016 European Guidelines on cardiovascular disease prevention in clinical practice (2017, positive): “Statins at doses that effectively reduce LDL-C by at least 50% also seem to halt progression or even contribute to regression of coronary atherosclerosis [373].”
- Progress and challenges in translating the biology of atherosclerosis (2011, background): “Unfortunately, at least one-quarter of high-risk patients who receive intensive statin therapy have LDL levels above current guideline-mandated goal”
- Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. (2008, methodology): “PAV was selected as the primary efficacyparameterbecausethisendpointhas exhibitedthelowestvariabilityinmultiple previous IVUS trials for a diverse range of therapeutic interventions.(10-12,14-16)”
- Nitric oxide synthases: regulation and function. (2012, background): “Together, these effects may contribute to the anti-atherogenic action of statins.(154,155)”
- European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invit (2007, positive): “Statins in the highest doses seem also to halt progression or induce regression of coronary atherosclerosis.(105,154) Therefore, they should be used as the drugs of first choice.”
- European guidelines on cardiovascular disease prevention in clinical practice: executive summary. (2007, positive): “105,154 Therefore, they should be used as the drugs of first choice.”